[1] SHI Y, MUCSI AD, NG G. Monosodium urate crystals in inflammation and immunity[J]. Immunol Rev, 2010, 233(1): 203. doi: 10.1111/j.0105-2896.2009.00851.x
[2] MARTINON F, PÉTRILLI V, MAYOR A, et al. Gout-associated uric acid crystals activate the NALP3 inflammasome[J]. Nature, 2006, 440(7081): 237. doi: 10.1038/nature04516
[3] HUGHES MM, O'NEILL LAJ. Metabolic regulation of NLRP3[J]. Immunol Rev, 2018, 281(1): 88. doi: 10.1111/imr.12608
[4] TANG YM, ZHANG L, ZHU SZ, et al. Gout in China, 1990-2017: the Global Burden of Disease Study 2017[J]. Public Health, 2021, 191: 33. doi: 10.1016/j.puhe.2020.06.029
[5] HUANG J, MA ZF, ZHANG Y, et al. Geographical distribution of hyperuricemia in mainland China: a comprehensive systematic review and meta-analysis[J]. Glob Health Res Policy, 2020, 5(1): 52. doi: 10.1186/s41256-020-00178-9
[6] CHEN J, PAN W, HSU C, et al. Impact of obesity and hypertriglyceridemia on gout development with or without hyperuricemia: a prospective study[J]. Arthritis Care Res(Hoboken), 2013, 65(1): 133. doi: 10.1002/acr.21824
[7] YU X, WANG T, HUANG S, et al. Evaluation of the causal effects of blood lipid levels on gout with summary level GWAS data: two-sample Mendelian randomization and mediation analysis[J]. J Hum Genet, 2021, 66(5): 465. doi: 10.1038/s10038-020-00863-0
[8] WANG P, SMITH SE, GARG R, et al. Identification of monosodium urate crystal deposits in patients with asymptomatic hyperuricemia using dual-energy CT[J]. RMD Open, 2018, 4(1): e000593. doi: 10.1136/rmdopen-2017-000593
[9] GONG T, YANG Y, JIN T, et al. Orchestration of NLRP3 inflammasome activation by ion fluxes[J]. Trends Immunol, 2018, 39(5): 393. doi: 10.1016/j.it.2018.01.009
[10] TAO JH, CHENG M, TANG JP, et al. Single nucleotide polymorphisms associated with P2X7R function regulate the onset of gouty arthritis[J]. PLoS One, 2017, 12(8): e0181685. doi: 10.1371/journal.pone.0181685
[11] TAO JH, ZHANG Y, LI XP, et al. P2X7R: a potential key regulator of acute gouty arthritis[J]. Semin Arthritis Rheum, 2013, 43(3): 376. doi: 10.1016/j.semarthrit.2013.04.007
[12] LI X, GAO J, TAO J. Purinergic signaling in the regulation of gout flare and resolution[J]. Front Immunol, 2021, 12: 785425. doi: 10.3389/fimmu.2021.785425
[13] JOOSTEN LA, NETEA MG, MYLONA E, et al. Engagement of fatty acids with Toll-like receptor 2 drives interleukin-1β production via the ASC/caspase 1 pathway in monosodium urate monohydrate crystal-induced gouty arthritis[J]. Arthritis Rheum, 2010, 62(11): 3237. doi: 10.1002/art.27667
[14] HU Y, LIN H, DIB B, et al. Cholesterol crystals induce inflammatory cytokines expression in a human retinal pigment epithelium cell line by activating the NF-κB pathway[J]. Discov Med, 2014, 18(97): 7.
[15] RAJAMÄKI K, LAPPALAINEN J, OÖRNI K, et al. Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: a novel link between cholesterol metabolism and inflammation[J]. PLoS One, 2010, 5(7): e11765. doi: 10.1371/journal.pone.0011765
[16] DUEWELL P, KONO H, RAYNER KJ, et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals[J]. Nature, 2010, 464(7293): 1357. doi: 10.1038/nature08938
[17] WALDMAN B, ANSQUER JC, SULLIVAN DR, et al. Effect of fenofibrate on uric acid and gout in type 2 diabetes: a post-hoc analysis of the randomised, controlled FIELD study[J]. Lancet Diabetes Endocrinol, 2018, 6(4): 310. doi: 10.1016/S2213-8587(18)30029-9
[18] DEROSA G, MAFFIOLI P, SAHEBKAR A. Plasma uric acid concentrations are reduced by fenofibrate: a systematic review and meta-analysis of randomized placebo-controlled trials[J]. Pharmacol Res, 2015, 102: 63. doi: 10.1016/j.phrs.2015.09.012
[19] DI MINNO A, LUPOLI R, CALCATERRA I, et al. Efficacy and safety of bempedoic acid in patients with hypercholesterolemia: systematic review and meta-analysis of randomized controlled trials[J]. J Am Heart Assoc, 2020, 9(15): e016262. doi: 10.1161/JAHA.119.016262
[20] WU J, ZHANG YP, QU Y, et al. Efficacy of uric acid-lowering therapy on hypercholesterolemia and hypertriglyceridemia in gouty patients[J]. Int J Rheum Dis, 2019, 22(8): 1445.
[21] HOTAMISLIGIL GS. Inflammation, metaflammation and immunometabolic disorders[J]. Nature, 2017, 542(7640): 177. doi: 10.1038/nature21363